Related Experiment Video
Updated: Jun 18, 2025
12:41
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
4.8K
Forming Single-Cell-Derived Colon Cancer Organoid Arrays on a Microfluidic Chip for High Throughput Tumor
Zihe Chen1, Jueming Chen1, Dongguo Lin1,2
1Department of Laboratory Medicine, The Second Affiliated Hospital, School of Medicine, South China University of Technology, Guangzhou 510180, China.
ACS Biomaterials Science & Engineering
|August 1, 2024
Summary
This study presents a microfluidic chip for high-throughput single-cell culture, enabling the generation of numerous tumor organoids (STOs) to study cancer heterogeneity and screen personalized therapies.
Area of Science:
- Biotechnology
- Cancer Research
- Microfluidics
Background:
- Single-cell-derived tumor organoids (STOs) are crucial for understanding tumor heterogeneity.
- High-throughput methods are needed for STO assays to meet research demands.
Purpose of the Study:
- To develop a microfluidic chip for high-throughput single-cell culture and STO generation.
- To investigate tumor heterogeneity and facilitate personalized drug screening using STOs.
Main Methods:
- A microfluidic chip with 30,000 nonadhesive microwells was designed for single-cell culture.
- Poly(ethylene glycol) (PEG) was used to create a nonadhesive environment, preventing cell loss and promoting stem cell expansion.
- Colon cancer cell lines (HCT116, HT29, SW480) were cultured to assess STO formation and characteristics.
Main Results:
- The microfluidic system achieved a STO formation rate of approximately 20%, generating over 800 STOs per culture.
- Analysis revealed heterogeneity among individual STOs, with smaller organoids showing increased invasion and drug resistance.
- The method successfully facilitated STO formation and expansion from single cells.
Conclusions:
- The developed microfluidic approach enables efficient generation of STOs for studying tumor heterogeneity.
- This technology holds promise for personalized therapy-focused drug screening and advancing cancer research.
